interesting read, page-5

re: interesting read...sbp exciting times ahead The new website has this page:

http://www.solbec.com.au/researchsbp2.html

Extract:

Compassionate use under the Australian Therapeutic Goods Administration Special Access Scheme. (SAS)

Solbec Pharmaceuticals have been using SBP002 under the Special Access Scheme since January 2001 and during that time we have treated in excess of 40 patients. The majority of these patients have been treated with systemic SBP002.

The drug is administered by a deep central line such as a PIC line, Hickmans or Portacath into the superior vena cava.

Patients with cancers as diversified as glioblastoma multiform, colon rectal, bladder, liver, metastasised melanoma to the lungs and other respiratory cancers have been treated during this period via infusion into the superior vena cava

Results of this Special Access Scheme treatments have been very encouraging and have provided significant data which will be used in future clinical studies.

Dosage is set at 3mg/kg body weight to a maximum of 200mg per day, although patients have received 1.5 to 4.5 mg/kg to a maximum of 250 mg/day. The following treatment protocols were used:

10 days on 14 days off 3 cycles
5 days on 9 days off 6 cycles
20 days on 1 cycle
28 days on 1 cycle

There have been no serious adverse reactions or deaths attributable to the treatments. The positive side effects that were observed included:

tumor size reduction
tumor marker reduction
extended life span
reduction in tumor growth rates
improved quality of life
reduced use of analgesia
reduction of swelling
pain reduction
improved appetite

Patients treated under the SAS are usually in very late stage disease with significant non-responsive tumor mass. On an average the patients are in the last few months of life.

The chance of success is low and the prognosis is bleak. Solbec have had some promising results with reports from treating physicians reporting tumor size reduction, reduction in tumor growth rates, extension of life as well as many other positive effects (see above).

SBP002 has been taken orally using enteric-coated tablets and has shown promising results in secondary endometrial cancer to the lung.

After 3 months treatment all but two of the patients tumors had disappeared (multiple nodules present before treatment) patient had been given approximately three months to live by oncologist and is still alive 18 months later.

A male with late stage pancreatic cancer went into long term remission after taking the tablets. A patient with metastatic melanoma was shown to have total remission of small lung tumors whilst on oral therapy.

A male with metastatic melanoma to the lung had aggressive disease with four tumors in Feb 2001 and 7 in mar 2001. The disease was non-responsive to standard chemotherapy. He inhaled SBP002 50mg per day for 14 days and had no further tumor growth.

Direct injection into large Basal cell and Squamous cell cancers on the face have shown very aggressive anti tumor activity. Figures 5 and 6 show facial tumors treated with intertumoral SBP002. Direct injection into a large lymphatic cancer of the neck resulted in eradication of the tumor.

There have been a significant number of similar cases with very good response. It is difficult to attribute the result to a particular treatment with SAS patients as they are often on more that one therapy. The circumstantial evidence for SBP002 is still convincing.

Figure 5: Basal Cell Carcinoma treated with SBP002
__________________________________

Gerry
http://www.hotcopper.com.au/post_thread.asp?fid=1&tid=54890&sym=SBP#138170